Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Next Previous
Trial Profile

Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remestemcel-L (Primary) ; Diphenhydramine; Hydrocortisone
  • Indications Adult respiratory distress syndrome; COVID 2019 infections; Inflammation
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors Mesoblast

Most Recent Events

  • 17 Feb 2021 Results presented in a Mesoblast Media Release.
  • 17 Feb 2021 According to a Mesoblast media release, data published in Pediatrics (Journal of the American Academy of Pediatrics).
  • 12 Feb 2021 Results (n=2) published in the Pediatrics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top